Phase I Trial of Oral Estramustine and 3-hr Infusional Paclitaxel for the Treatment of Hormone Refractory Prostate Cancer

REFERENCES

• Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer Statistics 2000. CA—Cancer J. Clin. 1999; 50: 7–33
   Web of Science ®Google Scholar
• Eisenberger M.A., Blumenstein B.A., Crawford E.D., Miller G., McLeod D.G., Loehrer P.J., Wilding G., Sears K., Culkin D.J., Thompson I.M., Bueschen A.J., Lowe B.A. Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer. N. Engl. J. Med. 1998; 339: 1036–1042
   PubMed Web of Science ®Google Scholar
• Yagoda A., Petrylak D. Cytotoxic Chemotherapy for Advanced Hormone-Resistant Prostate Cancer. Cancer 1993; 371: 1098–1109
   Google Scholar
• Perry C.A., McTavish D. Estramustine phosphate sodium: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1995; 7: 149–174
   Google Scholar
• Roth B.J., Yeap B.Y., Wilding G., Kasimis B., McLeod D., Loehrer P. Taxol in Advanced, Hormone Refractory Carcinoma of the Prostate. Cancer 1993; 72: 2457–2460
   PubMed Web of Science ®Google Scholar
• Hudes G.R., Nathan F., Khater C., Haas N., Cornfield M., Giantonio B., Greenberg R., Gomella L., Litwin S., Ross E., Roethke S., McAleer C. Phase II Trial of 96-Hour Paclitaxel Plus Oral Estramustine Phosphate in Metastatic Hormone Refractory Prostate Cancer. J. Clin. Oncol. 1997; 15: 3156–3163
   PubMed Web of Science ®Google Scholar
• Hudes G.R., Greenberg R., Krigel R.L., Fox S., Scher R., Litwin S., Watts P., Speicher L., Tew K., Comis R. Phase II Study of Estramustine and Vinblastine, Two Microtubule Inhibitors, in Hormone-Refractory Prostate Cancer. J. Clin. Oncol. 1992; 10: 1754–1761
   PubMed Web of Science ®Google Scholar
• Pienta K.J., Redman B., Hussain M., Cummings G., Esper P.S., Appel C., Flaherty L.E. Phase II Evaluation of Oral Estramustine and Oral Etoposide in Hormone-Refractory Adenocarcinoma of the Prostate. J. Clin. Oncol. 1994; 12: 2005–20012
   PubMed Web of Science ®Google Scholar
• Petrylak D.P., Macarthur B.R., O'Connor J., Shelton G., Judge T., Balog J., Pfaff C., Bagiella E., Heitjan D., Fine R., Zuech N., Sawczuk I., Benson M., Olsson C.A. Phase I Trial of Docetaxel with Estramustine in Androgen-Independent Prostate Cancer. J. Clin. Oncol. 1999; 17: 958–967
   PubMed Web of Science ®Google Scholar
• Picus J., Schultz M., Cochrane J. A Phase II Trial of Docetaxel in Patients with Hormone Refractory Prostate Cancer (HRPC): Long Term Results. Proc. ASCO 1999; 18: 314a
   Google Scholar
• Hudes G., Einhorn L., Ross E., Balsham A., Loehrer P., Ramsey H., Sprandio J., Entmacher M., Dugan W., Ansari R., Moncaco F., Hanna M., Roth B. Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients with Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III Trial. J. Clin. Oncol. 1999; 17: 3160–3166
   PubMed Web of Science ®Google Scholar
• Dahllof B., Billstrom A., Cabral F., Hartley-Asp B. Estramustine Depolymerizes Microtubules by Binding to Tubulin. Cancer Res. 1993; 53: 4573–4581
   PubMed Web of Science ®Google Scholar
• Stearns M.E., Wang M., Tew K.D. Estramustine Binds a MAP-1 Like Protein to Inhibit Microtubule Assembly In Vitro and Disrupt Microtubule Organization in DU-145 Cells. J. Cell Biol. 1988; 107: 2647–2656
   PubMed Web of Science ®Google Scholar
• Tishler R.B., Lamppu D.M., Park S., Price B.D. Microtubule-Active Drugs Taxol, Vinblasine, and Nocodazole Increase the Levels of Transcriptionally Active p53. Cancer Res. 1995; 55: 6021–6025
   PubMed Web of Science ®Google Scholar
• Belotti D., Vergani V., Drudis T. The Microtubule Affecting Drug Paclitaxel Has Antiangiogenic Activity. Clin. Cancer Res. 1996; 2: 1843–1849
   PubMed Web of Science ®Google Scholar
• Klauber N., Parangi S., Flynn E., Hamel E., D'Amato R.J. Inhibition of Angiogenesis and Breast Cancer in Mice by the Microtubule Inhibitors 2-Methoxyestradiol and Taxol. Cancer Res. 1997; 57: 81–86
   PubMed Web of Science ®Google Scholar
• Haldar S., Chintapalli J., Croce C.M. Taxol Induces bcl-2 Phosphorylation and Death of Prostate Cancer Cells. Cancer Res. 1996; 56: 1253–1255
   PubMed Web of Science ®Google Scholar
• Liu Q.-Y., Stein C.A. Taxol and Estramustine-Induced Modulation of Human Prostate Cancer Cell Apoptosis via Alteration in bcl-xL and bak Expression. Clin. Cancer Res. 1997; 3: 2039–2046
   PubMed Web of Science ®Google Scholar
• Garcia A.A., Keren-Rosenberg S., Parimoo D., Rogers M., Jeffers S., Koda R., Muggia F.M. Phase I and Pharmacologic Study of Estramustine Phosphate and Short Infusions of Paclitaxel in Women with Solid Tumors. J. Clin. Oncol. 1998; 16: 2959–2963
   PubMed Web of Science ®Google Scholar
• Bubley G.J., Carducci M., Dahut W., Dawson N., Daliani D., Eisenberger M., Figg W.D., Freidlin B., Halabi S., Hudes G., Hussain M., Kaplan R., Myers C., Oh W., Betrylak D.P., Reed E., Roth B., Sartor O., Scher H., Simons J., Sinibaldi V., Small E.J., Smith M.R., Trump D.L., Vollmer R., Wilding G. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. 1999; 17: 3461–3467
   PubMed Web of Science ®Google Scholar
• Gehl J., Boesgaard M., Passke T. Combined Doxorubicin and Paclitaxel in Advanced Breast Cancer: Effective and Cardiotoxic. Ann. Oncol. 1996; 7: 687–693
   PubMed Web of Science ®Google Scholar
• Millikan R., Logothetis C., Baker L.H., Gershenson D., Hanks G., Kantoff P., Lange P., Sandler H., Walsh P. Update of the NCCN Guidelines for Treatment of Prostate Cancer. Oncology 1997; 11: 180–195
   PubMedGoogle Scholar
• Peereboom D.M., Klein E., Olencki T., Connell C., Aaron R., Pratt S., Bukowskin R.M. Phase I Trial of Paclitaxel and Estramustine in Hormone Refractory Prostate Cancer. Proc. ASCO 1996; 15: 263a, abst 690
   Google Scholar
• Leitner S.P., Scoppetuelo M., Kanowitz J.M., Lowry P.A., Clyde J. Phase II Trial of Weekly One Hour Paclitaxel Plus Oral Estramustine Take the Day Before, of, and After Paclitaxel in Patients with Metastatic Hormone Refractory Prostate Cancer. Proc. ASCO 1999; 18: 345a, abst 1331
   Google Scholar
• Taneja S., Chachoua A., Ferrari A., Utate M., Kutz L., Stone N., Stock R., Baldwin Y., Lepor H., Muggia F. Phase I Trial of Taxol/Estramustine in Patients with Hormone Refractory Prostate Cancer. Proc. ASCO 1999; 18: 354a, abst 1364
   Google Scholar
• Haas N., Garay C., Roth B., Babb J., Rogatko A., Entmacher M., Weinstein A., Minitti C., Finch D., Yeslow G., Gillon T., Hudes G. Weekly Paclitaxel by 3-Hour Infusion Plus Oral Estramustine in Metastatic Hormone Refractory Prostate Cancer. Proc. ASCO 1999; 18: 340a, abst 1311
   Google Scholar
• Trivedi C., Redman B., Flaherty L., Kucuk O., Du W., Heilbrun L.K., Hussain M. Weekly 1 Hour Infusion of Paclitaxel: Clinical Feasibility and Efficacy in Patients with Hormone-Refractory Prostate Cancer. Cancer 2000; 89: 431–436
   PubMed Web of Science ®Google Scholar
• Smith D.C., Esper P., Strawderman M., Redman B., Pienta K.J. Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate Cancer. J. Clin. Oncol. 1999; 17: 1664–1671
   PubMed Web of Science ®Google Scholar
• Storlie J.A., Buckner J.C., Wiseman G.A., Burch P.A., Hartmann L.C., Richardson R.L. Prostate Specific Antigen Levels and Clinical Response to Low-Dose Dexamethasone for Hormone-Refractory Metastatic Prostate Carcinoma. Cancer 1995; 76: 96–100
   PubMed Web of Science ®Google Scholar
• Weitzman A.L., Shelton G., Zuech N., Owen C.E., Judge T., Benson M., Sawczuk I., Katz A., Olsson C., Bagiella E., Pfaff C., Newhouse J.H., Petrylak D.P. Dexamethasone Does Not Significantly Contribute to the Response Rate of Docetaxel and Estramustine in Androgen Independent Prostate Cancer. J. Urol. 2000; 163: 834–837
   PubMed Web of Science ®Google Scholar